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OBJECTIVES This study was designed to compare the dose response of dalteparin versus unfractionated
heparin (UFH) on the activated clotting time (ACT), and to determine whether the ACT can
be used to monitor intravenous (IV) dalteparin during percutaneous coronary intervention
(PCI).
BACKGROUND The use of low molecular weight heparin (LMWH) during PCI has been limited by the
presumed inability to monitor its anticoagulant effect using bedside assays.
METHODS This study was performed in three phases. In vitro, ACTs were measured on volunteer (n 
10) blood samples spiked with increasing concentrations of dalteparin or UFH. To extend
these observations in vivo, ACTs were then measured in patients (n  15) who were
sequentially treated with IV dalteparin and then UFH. Finally, a larger monitoring study was
undertaken involving patients (n  110) who received dalteparin 60 or 80 international U
(IU)/kg alone or followed by abciximab. We measured ACT (Hemochron), activated partial
thromboplastin time (aPTT), plasma anti-Xa and anti-IIa levels, tissue factor pathway
inhibitor (TFPI) concentration, and plasma dalteparin concentration.
RESULTS Dalteparin induced a significant rise in the ACT with a smaller degree of variance as
compared to UFH. Five min after administration of IV dalteparin 80 IU/kg the ACT
increased from 125 s (122 s, 129 s) to 184 s (176 s, 191 s) (p  0.001). The aPTT, anti-Xa
and anti-IIa activities, and TFPI concentration also demonstrated significant increases
following IV dalteparin.
CONCLUSIONS The ACT and aPTT are sensitive to IV dalteparin at clinically relevant doses. These data
suggest that the ACT may be useful in monitoring the anticoagulant effect of intravenously
administered dalteparin during PCI. (J Am Coll Cardiol 2003;41:394–402) © 2003 by the
American College of Cardiology Foundation
Advantages of low molecular weight heparin (LMWH)
over unfractionated heparin (UFH) include greater bioavail-
ability (1), a decreased incidence of thrombocytopenia (2),
and resistance to inactivation by platelet factor 4 (3). The
greater bioavailability gives LMWH the potential for sub-
cutaneous administration without the need for monitoring
(4–6). This advantage has led to a significant increase in the
use of LMWH in the management of unstable coronary
syndromes. Therefore an increasing number of patients
referred for angiography and possible percutaneous coronary
intervention (PCI) are arriving at the cardiac catheterization
laboratory having received subcutaneous LMWH at various
intervals from the time of subcutaneous injection. Though
studies have demonstrated that LMWH can be used safely
during PCI (7,8), an optimal strategy for the management
of the anticoagulation of these patients has not been
defined.
Current management of anticoagulation with UFH in
the angioplasty setting uses the ACT to guide dosing (9,10).
The ACT is a broadly used point-of-care assay, which
appears to be sensitive to thrombin inhibition (11) and
relatively insensitive to factor Xa inhibition (12). Because
dalteparin is a LMWH that retains substantial anti-IIa
activity (13), we hypothesized that the ACT would be
sensitive to intravenous (IV) dalteparin at clinically relevant
doses. Thus, the purpose of this study was 1) to compare the
dose-response relationship between IV dalteparin and the
ACT to the relationship between UFH and the ACT and
2) to determine whether the anticoagulant effects of IV
dalteparin could be monitored during PCI by measuring the
changes in the ACT.
METHODS
The Institutional Review Board of the Mount Sinai Hos-
pital, New York, NY, approved all protocols for this study.
This study was performed in three phases. In the first phase,
the effect of increasing concentrations of dalteparin on the
ACT was studied and compared with changes induced by
increasing concentrations of UFH in volunteer blood sam-
ples in vitro. To extend these observations in vivo and to
allow for a paired comparison, the second phase of the study
involved the generation of dose-response curves by sequen-
tially administering dalteparin and UFH to the same pa-
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tient. The third phase comprised a larger observational
monitoring study in which patients undergoing cardiac
catheterization or PCI were treated with dalteparin alone or
dalteparin plus abciximab.
Comparative effects of dalteparin and UFH on the ACT
in vitro. An in vitro comparative study was performed
initially. This dose-response study used blood samples from
10 healthy volunteers (4 men and 6 women; mean age 39.4
 13.5 years). Twelve milliliters of blood were collected
from each of the healthy volunteers, free of medication, via
venipuncture of the antecubital vein using 21-gauge needles.
Dalteparin (12,500 IU/ml) and UFH (1,000 USP U/ml)
were both diluted with saline to 50 U/ml and added to
aliquots of whole blood to achieve final concentrations of 0,
0.25, 0.5, 0.75, 1.0, and 1.25 U/ml. These concentrations
were chosen because they yielded changes in the ACT that
were within a clinically relevant range (125 to 296 s for
UFH). These aliquots were immediately injected into
CA510 tubes (International Technidyne, Edison, New
Jersey) containing the activator Celite (diatomaceous earth)
and agitated vigorously. The CA510 tubes were then placed
in the Hemochron 801 (International Technidyne, Edison,
New Jersey) and the ACT was performed in duplicate.
Results were recorded in seconds.
IN VIVO DOSE RESPONSE. To extend our observations in
vivo, we compared the effects of 80 IU/kg of IV dalteparin
to a standard interventional dose of IV UFH (70 U/kg). The
key feature of this in vivo dose-response study was that
dalteparin and UFH were given sequentially to the same
patient, thereby allowing for a paired comparison. Fifteen
patients (mean age 61.1  10.1 years; 67% men) with a
diagnosis of stable angina, asymptomatic with positive
exercise stress test, unstable angina, non–Q-wave myocar-
dial infarction (MI), or chest pain post-MI undergoing
coronary angiography (n  5) or PCI (n  10) were
enrolled after informed consent. The demographics of this
study population are shown in Table 1. All patients under-
going PCI were given aspirin and clopidogrel before the
procedure; abciximab was given to three of the 10 PCI
patients at the discretion of the operator. Patients received
a total of 80 IU/kg IV dalteparin administered in two
separate boluses of 40 IU/kg each at baseline and at 5 min.
After a washout period of at least 12 h, a total of 70 U/kg
IV UFH was administered as a split bolus of 40 U/kg and
30 U/kg at baseline and at 5 min, respectively. Blood
samples were drawn at baseline, and 5 and 10 min after IV
drug administration from the arterial access sheath (dalte-
parin) or antecubital vein (UFH) into vacutainers contain-
ing one volume 3.8% sodium citrate (Becton Dickinson,
Franklin Lakes, New Jersey). The anticoagulant effects of
both IV dalteparin and UFH were assessed by measuring
the ACT, activated partial thromboplastin time (aPTT),
anti-Xa levels, and anti-IIa levels.
Monitoring study. On the basis of the observations from
the in vitro and in vivo dose-response studies, we undertook
an observational monitoring study in which patients were
given either 60 or 80 IU/kg IV dalteparin. In this phase of
the study, there was no UFH comparator arm.
PATIENT POPULATION. The study population was derived
from patients with a diagnosis of stable angina, asymptom-
atic with positive exercise stress test, unstable angina,
non–Q-wave MI, or chest pain post-MI undergoing cardiac
catheterization at Mount Sinai Hospital, New York, New
York. A total of 110 patients were enrolled over an
eight-month period (4/00 to 12/00). Of the 110 patients, 24
(22%) underwent coronary angiography and 86 (78%) un-
derwent PCI. The demographics of the monitoring study
population are shown in Table 1. A diagram of patient flow
is shown in Figure 1. Informed consent was obtained from
each patient before enrollment.
Exclusion criteria for the in vivo dose response and
monitoring studies included MI within 24 h, active internal
bleeding, recent (within six weeks) gastrointestinal or gen-
itourinary bleeding of clinical significance, history of cere-
brovascular accident (CVA) within two years or CVA with
a residual neurologic deficit, bleeding diathesis, administra-
tion of oral anticoagulant within seven days unless pro-
thrombin time was 1.2 times control, thrombocytopenia
(100,000/l), recent (within six weeks) major surgery or
Abbreviations and Acronyms
ACT  activated clotting time
aPTT  activated partial thromboplastin time
CVA  cerebrovascular accident
IU  international unit
IV  intravenous
LMWH  low molecular weight heparin
MI  myocardial infarction
PCI  percutaneous coronary intervention
TFPI  tissue factor pathway inhibitor
UFH  unfractionated heparin







Age 61.1  10.1 61.8  11.6
Men, n (%) 10 (67) 72 (66)
Hypertension, n (%) 13 (87) 88 (80)
Lipidemia, n (%) 11 (73) 86 (78)
Smoking, n (%) 4 (27) 53 (48)
Diabetes, n (%) 8 (53) 58 (53)
Previous MI, n (%) 7 (47) 19 (17)
Previous CABG, n (%) 1 (7) 10 (9)
Previous PCI, n (%) 9 (60) 44 (40)
Left anterior descending, n (%) 1 (7) 36 (33)
Circumflex, n (%) 2 (14) 22 (20)
Right coronary artery, n (%) 3 (20) 32 (29)
Saphenous vein graft 0 (0) 2 (2)
In-stent restenosis, n (%) 0 (0) 1 (1)
Data presented as mean  SD or number (percentage) of patients.
CABG  coronary artery bypass graft; MI  myocardial infarction; PCI 
percutaneous coronary intervention.
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trauma, intracranial neoplasm, arteriovenous malformation
or aneurysm, severe uncontrolled hypertension 180/100
mm Hg on enrollment to the study, use of IV dextran before
PCI, or hypersensitivity to one of the study drugs or their
components. Because excretion of dalteparin is predomi-
nantly renal, patients with creatinine 2.0 were also ex-
cluded. Enrolled patients being treated with IV UFH had
their infusion of UFH discontinued at least 4 h before
catheterization. Patients too unstable to allow for heparin
cessation on call to the cardiac catheterization laboratory
were excluded. Patients with a baseline ACT 160 s were
excluded because an ACT above this level was likely due to
residual heparin effect that could confound the analysis of
dalteparin’s effect on the indices of coagulation. Patients
who had received subcutaneous dalteparin (n  8) before
catheterization were not excluded on the basis of the initial
ACT. In these patients, an ACT 160 s mandated a
reduced dose (40 IU/kg) of dalteparin.
STUDY MEDICATIONS. The effects of ACT, aPTT, and
other coagulation parameters were studied using two doses
of IV dalteparin (60 IU/kg or 80 IU/kg), with and without
abciximab. The initial 52 consecutive patients received 60
IU/kg IV dalteparin, and the subsequent 50 consecutive
patients received 80 IU/kg IV dalteparin. An initial dose of
60 IU/kg was selected on the basis of previously published
data (14). The dose of 80 IU/kg was chosen on the basis of
a 20 IU/kg increment (40 IU/kg to 60 IU/kg) used in the
aforementioned study by Kereiakes et al. (14).
A total of 110 patients received IV dalteparin. Of the 110
patients receiving IV dalteparin, 52 (47%) received a dose of
60 IU/kg. Thirty-four of these 52 patients (65%) also
received abciximab (0.25 mg/kg bolus and 0.125 g/kg/h
maintenance infusion). Of the 110 patients receiving IV
dalteparin, 50 (46%) received a dose of 80 IU/kg. Twenty-
four of these 50 patients (48%) also received abciximab.
Abciximab was given at the operator’s discretion and was
administered after the 10 min blood draw. All patients
undergoing PCI were given aspirin and clopidogrel before
the procedure.
SUBCUTANEOUS SUBSTUDY. Of the 110 patients, eight re-
ceived a single subcutaneous injection of dalteparin 120
IU/kg during the noninvasive phase of their hospital course.
Using data from the dose-response study, it was arbitrarily
decided that immediately before PCI patients with an ACT
160 s (n  2) were to receive an IV dalteparin 40 IU/kg
bolus and patients with ACT 160 s (n  6) were to
receive an IV dalteparin 60 IU/kg bolus. Four of the eight
patients received abciximab (0.25 mg/kg bolus and 0.125
g/kg/h maintenance infusion) 10 min after dalteparin at
the operator’s discretion.
BLOOD SAMPLES. Six blood samples were collected from
the arterial access sheath in sodium citrate vacutainers at the
following time points: baseline and 5, 10, 20, 40, and 60
min after IV dalteparin in the observational monitoring
study. Patients in the subcutaneous substudy had their blood
samples drawn directly from the antecubital vein at baseline
and then every hour following dalteparin subcutaneous
administration until the time of the procedure. Blood
samples were centrifuged at 3,000 g for 15 min at 22°C.
Platelet-poor plasma was collected and aliquoted into 2 ml
eppendorf tubes and stored at 70°C. Frozen samples were
Figure 1. Patient flow for the in vitro dose response (volunteers), in vivo dose response, and monitoring studies. Abx  administration of abciximab; IV
 intravenous; SC  subcutaneous.
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transported on dry ice to the Thrombosis and Hemostasis
Research Laboratory at Loyola Medical Center (Maywood,
Illinois). Arterial access sheaths were removed 2 to 4 h after
completion of the procedure.
MONITORING OF THE ANTICOAGULANT EFFECT. ACT.
Two milliliters of blood was collected in a FTCA510 tube
(International Technidyne, Edison, New Jersey) with the
activator Celite. The tube was vigorously shaken and placed
in the Hemochron 8000 (International Technidyne, Edi-
son, New Jersey). Results were recorded in seconds.
aPTT. Samples were analyzed using STA-PTT A 5, a
reagent containing rabbit cerebral cephalin and silica (Di-
agnostica Stago, Asnieres-Sur-Seine, France) on the
STA-R (Diagnostica Stago, Gennevilliers, France). Results
were recorded in seconds.
ANTIPROTEASE ASSAYS. Both the anti-Xa (15) and anti-IIa
(16) assays were performed as previously described. Anti-Xa
and anti-IIa activities were both adjusted to a reference
baseline value of 0.0 IU/ml in all cohorts.
HEPTEST ASSAY. Heptest was performed on a fibrometer,
according to Yin et al. (17). Heptest activity was adjusted to
a reference baseline value of 0.0 IU/ml in all cohorts.
QUANTIFICATION OF TFPI. A tissue factor pathway inhibi-
tor (TFPI) enzyme linked immunoabsorbent spectrophoto-
metric assay was performed (18,19). Results were expressed
as nanograms/milliliter.
Assessment of safety. Minor and major bleeding was
defined according to the criteria used by the Thrombolysis
in Myocardial Infarction (TIMI) Trial (20). Severe throm-
bocytopenia was defined by a platelet count below 50,000/
l. Mild thrombocytopenia was defined as a platelet count
below 100,000/l or a count below 50% of the baseline
value. The degree of thrombocytopenia was assessed post-
procedurally after either dalteparin alone or combination
dalteparin and abciximab therapy. Myocardial infarction
was defined as an elevation in CK-MB three times the
upper limit of normal. Blood for CK-MB analysis was
drawn before PCI and every 8 h for 24 h.
Statistical analysis. Patient demographic and coagulation
parameter data were described using mean (95% confidence
interval) and mean  SD where indicated. Analysis of
variance was used to compare the effect on coagulation
parameters across the six sampling time points for each dose
of dalteparin, 60 IU/kg and 80 IU/kg. Normality was tested
using the Shapiro-Wilkes test for small samples. All data
passed normality with the exception of the ACT data from
the sequential dalteparin and UFH group, which were
transformed using logarithms and retested. The variability
of the ACT response to dalteparin and UFH were deter-
mined by calculating the coefficient of variance (mean/SD
 100) for both drugs in the in vitro and in vivo dose-
response studies. To determine whether these variations
were similar, an F test was performed as previously de-
scribed (21). All statistical analyses were performed using
SPSS version 10.0. A two-tailed p  0.05 was considered
statistically significant.
RESULTS
Comparative effects of dalteparin and UFH on the ACT
in vitro. Dalteparin and UFH both demonstrated a signif-
icant dose response with respect to the ACT (Fig. 2).
Although a greater slope was seen with UFH, a moderate
slope was present in the dalteparin-induced curve. The
degree of variability in ACT at the highest concentration
(1.25 U/ml) as measured by the coefficient of variance was
Figure 2. In vitro dose-response of the activated clotting time (ACT) as a function of increasing concentration of anticoagulant in whole blood. Samples
were derived from healthy volunteers (n  10) and aliquots (n  200) were treated with increasing doses of either unfractionated heparin (UFH) (circles)
or dalteparin (squares). Data presented as mean  SD.
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numerically, but not statistically, lower for dalteparin than
for UFH (8.5 vs. 11.4; p  0.26).
Comparative effects of dalteparin and UFH on the ACT
in vivo. As was seen in the in vitro experiments, a signif-
icant rise in ACT was discernible as the dose of both
dalteparin and UFH was increased in vivo (Fig. 3). The
ACT of patients receiving 80 IU/kg dalteparin demon-
strated a significantly lower coefficient of variance as com-
pared to patients receiving 70 U/kg UFH (12.5 vs. 23.6; p
 0.03).
After the boluses of dalteparin and UFH were adminis-
tered, the ACT, aPTT, anti-Xa activity, and anti-IIa
activity all increased (Table 2). The increases observed in
the ACT after dalteparin administration from samples
drawn at the 5 and 10 min time points demonstrated a
significant but weak correlation to the elevations in anti-Xa
(r  0.47; p  0.01) and anti-IIa activities (r  0.37; p 
0.048). After UFH administration numerically weaker cor-
relations were seen between the increases in the ACT and
the elevations in anti-Xa (r  0.06; p  0.75) and anti-IIa
activities (r  0.26; p  0.18) from samples collected at the
5- and 10-min time points.
Monitoring study. RESPONSE OF COAGULATION PARAME-
TERS TO IV DALTEPARIN. The changes in coagulation pa-
rameters for the 102 patients in the monitoring study who
received IV dalteparin without pretreatment with subcuta-
neous dalteparin are listed in Table 3. Following IV dalte-
parin 60 or 80 IU/kg, there was a significant elevation in the
ACT at 5 min (p  0.001) and throughout the 60-min
observation period (p  0.001). A rise in the ACT of at
least 20% from baseline values was seen in every patient
studied. In comparison to 60 IU/kg, an 80 IU/kg IV dose of
dalteparin led to a significantly greater elevation in the ACT
that was sustained throughout the 60-min observation
period (p  0.001). Similar trends were seen in the aPTT,
in the plasma levels of anti-Xa and anti-IIa activity, and
Heptest (Table 3). These trends were also present in the
group of patients who were treated with dalteparin alone
Figure 3. In vivo dose-response of the ACT as a function of the cumulative doses of UFH (circles) or dalteparin (squares). Patients (n  15) initially
received dalteparin (40  40 IU/kg 5 min apart, for a total of 80 IU/kg), and then, following a 12-h delay to allow elimination of dalteparin and return
of the ACT to baseline, received UFH (40  30 U/kg 5 min apart, for a total of 70 U/kg). Data presented as mean  SD. Abbreviations as in Figure 2.
Table 2. Changes in Coagulation Parameters Induced by Intravenous Dalteparin and UFH
Coagulation Parameters
Drug dose ACT (s) aPTT (s) Anti-Xa (IU/ml) Anti-IIa (IU/ml)
Dalteparin baseline 123  11 28.5  2.3 0.0  0.0 0.0  0.0
Dalteparin 40 IU/kg 157  16 55.6  15.0 1.0  0.6 0.4  0.5
Dalteparin 80 IU/kg 192  24 88.6  21.7 1.9  0.8 1.1  0.5
UFH baseline 132  7 29.4  2.7 0.0  0.0 0.0  0.0
UFH 40 U/kg 207  37 106.5  13.3 0.5  0.3 0.6  0.3
UFH 70 U/kg 259  61 110.0  0.0 1.1  0.5 0.9  0.3
Data presented as mean  SD. Baseline anti-Xa activity and anti-IIa activity are reference values for assays used. Patients (n 
15) were treated sequentially with dalteparin and then, after a minimum washout period of 12 h, with UFH.
ACT  activated clotting time; aPTT  activated partial thromboplastin time; IU  international units; UFH 
unfractionated heparin.
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(Fig. 4). Note that in this group of patients, a numerical
decline in the ACT at 60 min was noted in comparison
to the peak levels at 10 min (156 vs. 167 s for 60 IU/kg
dose, p  0.09; 175 vs. 187 s for the 80 IU/kg dose, p 
0.10).
The ACT and aPTT values generated from samples
drawn at baseline and 5 min post-dalteparin were correlated
(r  0.82; p  0.001). Elevations in anti-Xa and anti-IIa
activity were weakly correlated with changes in the ACT
(r 0.26; p 0.012 and r 0.31; p 0.002, respectively).




(IU/kg) Baseline 5 min 10 min 20 min 40 min 60 min
ACT (s) 60 128 (123, 132) 175 (167, 182) 177 (171, 183) 190 (182, 198) 186 (173, 198) 175 (165, 184)
80 125 (122, 129) 184 (176, 191) 187 (180, 193) 189 (182, 195) 186 (179, 193) 180 (174, 187)
aPTT (s) 60 31.0 (27.5, 34.5) 63.6 (57.0, 70.3) 63.7 (57.7, 69.7) 70.4 (61.8, 79.1) 66.2 (57.3, 75.1) 59.0 (52.9, 65.1)
80 29.0 (27.7, 30.3) 78.6 (71.7, 85.4) 78.4 (72.7, 84.1) 83.3 (76.4, 90.2) 82.7 (75.3, 90.1) 77.5 (70.1, 84.8)
Anti-Xa (IU/ml) 60 0.0 1.15 (1.03, 1.27) 1.14 (1.04, 1.24) 1.00 (0.91, 1.11) 0.86 (0.75, 0.97) 0.71 (0.60, 0.82)
80 0.0 1.55 (1.43, 1.68) 1.48 (1.38, 1.58) 1.45 (1.31, 1.58) 1.24 (1.08, 1.39) 1.03 (0.86, 1.21)
Anti-IIa (IU/ml) 60 0.0 0.65 (0.57, 0.71) 0.65 (0.59, 0.71) 0.58 (0.51, 0.64) 0.49 (0.40, 0.59) 0.38 (0.32, 0.44)
80 0.0 0.81 (0.76, 0.87) 0.77 (0.72, 0.82) 0.73 (0.67, 0.79) 0.62 (0.55, 0.69) 0.48 (0.40, 0.57)
Heptest (IU/ml) 60 0.0 1.39 (1.26, 1.51) 1.34 (1.25, 1.44) 1.23 (1.13, 1.33) 1.04 (0.94, 1.14) 0.89 (0.77, 1.01)
80 0.0 1.74 (1.59, 1.88) 1.69 (1.57, 1.82) 1.66 (1.52, 1.81) 1.42 (1.27, 1.56) 1.19 (1.02, 1.35)
TFPI (ng/ml) 60 57 (52, 63) 411 (372, 450) 465 (433, 497) 449 (417, 481) 396 (360, 432) 314 (278, 350)
80 46 (41, 51) 341 (306, 377) 356 (328, 384) 356 (322, 390) 308 (275, 340) 273 (234, 312)
Values are presented as mean (95% CI). *34 of the 52 patients treated with 60 IU/kg, and 24 of the 50 patients treated with 80 IU/kg received abciximab. p  0.001 for all
timepoints compared to baseline.
CI  confidence interval; TFPI  tissue factor pathway inhibitor. Other abbreviations as in Table 2.
Figure 4. Indices of coagulation following administration of intravenous (IV) dalteparin 60 IU/kg (n  18) and IV dalteparin 80 IU/kg (n  26). Data
presented as mean (95% confidence interval). * p 0.001 for all time points compared to baseline. Black bars dalteparin 60 IU/kg; gray bars dalteparin
80 IU/kg.
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RESPONSE TO SUBCUTANEOUS DALTEPARIN ADMINISTRA-
TION. Eight patients in the study received subcutaneous
dalteparin 120 IU/kg at least 2 h before PCI. There was an
increase in ACT from a baseline of 126  10 s to 146 
11 s at 1 h, with a peak value of 151  13 s at 2 h (p 
0.001). Similarly, aPTT rose from a baseline of 28.2 2.5 s
to 36.6 6.1 s at 1 h (p 0.001) and to 38.7 5.8 s at 2 h
(p  0.001). Anti-Xa activity increased to 0.56  0.24
IU/ml at 1 h and 0.70  0.18 IU/ml at 2 h (p  0.001).
These patients received IV dalteparin 40 IU/kg (n 2) or
60 IU/kg (n  6) during PCI depending on the ACT
measured immediately after sheath insertion. In those pa-
tients receiving IV dalteparin 40 IU/kg, 5 min after the IV
bolus the ACT increased from 160  1 s to 220  10 s;
aPTT increased from 42.2  13.3 s to 71.6  10.7 s and
anti-Xa activity increased from 0.79  0.4 IU/ml to 1.21 
0.4 IU/ml. In those patients receiving IV dalteparin 60
IU/kg at 5 min after the IV bolus, the ACT increased from
141 13 s to 172 20 s (p 0.001); aPTT increased from
36.7  2.6 s to 76.3  12.2 s (p  0.001) and anti-Xa
activity increased from 0.71  0.26 IU/ml to 1.79  0.64
IU/ml (p  0.006).
Safety outcomes. DEATH, MI, AND URGENT REVASCULAR-
IZATION. There was no death or urgent revascularization
during the hospital course of the study population. Two of
the 96 PCI patients patient had MI (2.1%).
BLEEDING RATES IN PATIENTS UNDERGOING PCI. One pa-
tient in the IV dalteparin 80 IU/kg and abciximab cohort
suffered major bleeding requiring transfusion, yielding a
major bleeding rate of 1.0% (1/96). Two patients in the IV
dalteparin 80 IU/kg and abciximab cohort and one each in
the in vivo dose-response study and subcutaneous dalteparin
120 IU/kg cohort had minor bleeding, yielding a minor
bleeding rate of 4.2% (4/96). No patients with minor
bleeding required blood transfusion.
EPISODE OF THROMBOCYTOPENIA. One patient in the IV
dalteparin 80 IU/kg and abciximab cohort experienced an
episode of severe thrombocytopenia with no sequelae. There
were no episodes of mild thrombocytopenia.
DISCUSSION
This is the first study to prospectively analyze the effects of
IV dalteparin on the ACT. Our findings suggest that the
ACT may constitute a reliable assay for monitoring dalte-
parin during PCI for the following reasons. First, the
elevation is significant and rapidly detectable; within 5 min
of receiving IV dalteparin 80 IU/kg, the ACT increased on
average 59 s (Table 3). Second, there is a highly significant
dose-response relationship in vitro (r 0.99) (Fig. 2) and in
vivo (r  0.76) (Fig. 3). A dose response is also demon-
strated by the fact that patients receiving IV dalteparin 80
IU/kg experienced a significantly greater rise in their ACT
in comparison with those receiving 60 IU/kg. Third, in
comparison to the rise in the ACT induced by UFH, there
appears to be less variance in the dalteparin-induced eleva-
tions in the ACT both in vitro and in vivo. Fourth, the
increase in ACT was sustained for a period of time relevant
to current interventional practice (40 min, with a decline in
values at approximately 60 min for patients treated with
dalteparin alone). This raises the possibility that a decline in
the ACT to a targeted level (for example, 150 s) could
potentially be used to determine the timing of sheath
removal. Finally, these observations are consistent with
previous reports. In a study by Kereiakes et al. (14), patients
treated with either 40 IU/kg or 60 IU/kg of dalteparin IV
achieved mean ACTs 30 min after administration of 166 
28 s and 180  38 s, respectively. Similarly, in a study using
IV enoxaparin during PCI the mean ACT increased from
130  19 to 188  29 s 5 min after administration (7).
These previously reported data support the notion that the
ACT may be useful in monitoring the effects of intrave-
nously administered LMWH.
To determine whether the elevation seen in the ACT
following IV dalteparin occurred in isolation or in conjunc-
tion with changes in other indices of anticoagulation, the
aPTT, plasma anti-Xa and anti-IIa activities, and TFPI
concentration were also measured. The aPTT rose signifi-
cantly after IV dalteparin administration and to a level
traditionally regarded as therapeutic in the context of
medical management for unstable angina (1.5- to 2-fold
above baseline) (22). The aPTT demonstrated a significant
correlation (r  0.82) with the ACT, supporting the notion
that the elevated ACT values post-dalteparin reflected an
anticoagulated state. Studies have shown both the ACT and
aPTT to be prolonged by direct thrombin inhibitors (11,23)
and to be relatively insensitive to Factor Xa inhibition
(12,24). These observations suggest that the rise in the
ACT documented in the present study was more likely due
to dalteparin’s anti-IIa activity than to its anti-Xa activity. A
theoretic advantage of factor IIa inhibition, versus factor Xa
inhibition, is that inhibition of thrombin may prevent
feedback activation of factors V and VIII (25,26).
Our findings of poor correlations between the ACT and
anti-Xa and anti-IIa activities indicate that dalteparin-
induced changes in the ACT cannot be accounted for solely
on the basis of dalteparin’s anti-Xa and anti-IIa effects.
Despite the poor correlation in this study between the ACT
and plasma anti-Xa and anti-IIa activities, as well as
ambiguity in the literature regarding a correlation between
the ACT and anti-Xa activity in UFH-treated patients
(27,28), monitoring of UFH with the ACT to achieve
target levels between 200 and 300 s has become a generally
accepted standard in interventional practice (29). Further-
more, unlike anti-Xa and anti-IIa levels, the ACT has been
correlated to clinical outcomes (10,30). One explanation for
the observation that the ACT appears to correlate better to
clinical outcomes than to specific levels of factor Xa or IIa
inhibition is that the ACT is influenced by a variety of
factors that collectively determine the blood’s propensity to
thrombose. For example, antiplatelet agents have been
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noted to increase the ACT (31). In addition, both daltepa-
rin and UFH affect the coagulation mechanism at multiple
levels. Antithrombin (whether potentiated by LMWH or
UFH) not only exerts anti-Xa and anti-IIa effects, but also
has been shown to inhibit factors XIIa (32), XIa (33,34),
and IXa (35,36) of the intrinsic coagulation pathway. These
agents also induce the release of TFPI (37) and may alter
the inducibility of tissue factor on monocytes, thereby
providing additional mechanisms to retard thrombus for-
mation. Seen in this light, it is hardly surprising that weak
correlations were found between the ACT and specific
anti-Xa and anti-IIa levels.
Others have proposed that rather than using the ACT,
the effects of LMWH in patients undergoing PCI would be
better gauged by measuring anti-Xa levels (28,38). How-
ever, these observations pertain to LMWH administered
subcutaneously and to a specific formulation, enoxaparin,
that has a diminished anti-IIa effect in comparison to
dalteparin (13). Moreover, measurement of anti-Xa activity
would assess the action of LMWH on an isolated (albeit
important) step of the cascade, but would not take into
account the multiple levels at which a LMWH acts (factors
XIIa, XIa, IXa, and TFPI as noted earlier). Additionally, to
our knowledge previous clinical studies have demonstrated
only weak correlations between anti-Xa levels and thrombus
formation (39,40), and reported conflicting data on the
relationship between anti-Xa levels and the incidence of
hemorrhage (40–42). In contrast, a recent study by Chew et
al. demonstrated a significant relationship between the
ACT and ischemic/bleeding events after PCI in patients
receiving UFH (10). Furthermore, anti-Xa assays used for
monitoring display interassay variability depending on assay
technique (43) or type (44) and are not readily available as
a bedside device. Thus, it should not be assumed a priori
that anti-Xa activity monitoring would be superior to
monitoring the ACT in patients receiving intravenous
LMWH.
Point-of-care monitoring of the effects of LMWH may
be particularly important in patients with morbid obesity or
renal dysfunction (26,45,46), two populations in whom
rigorous dosing studies have not been reported (46). Addi-
tional benefits of monitoring may include detection of errors
in IV administration (47) and the potential for dose adjust-
ment in patients receiving antithrombotic, fibrinolytic, or
antiplatelet therapy before PCI.
Study limitations. There are several limitations associated
with the study. First, ACTs were measured using the
Hemochron system, and thus our data may not be readily
extrapolated to the Hemotech system (Medtronic, Parker,
Colorado) used in many cardiac catheterization laboratories.
Second, the study design was nonrandomized and open
label. Third, there was no comparator arm with heparin
alone in the monitoring study. Fourth, abciximab was the
lone adjunctive glycoprotein IIb/IIIa inhibitor used, and
therefore the results may not apply to patients receiving
eptifibatide or tirofiban. Fifth, our findings may not be
generalized to all LMWHs; the effect of dalteparin on the
ACT, aPTT, and other tests may differ from other LMWH
agents because of differences in the ratios of anti-Xa:anti-IIa
activity. The lower anti-Xa:anti-IIa ratio for dalteparin
compared to enoxaparin (2.7 vs. 3.8), for example, may
result in greater sensitivity of anti-IIa dependent tests for
dalteparin than for enoxaparin. Finally, blood samples were
collected for only 60 min after the initial dalteparin bolus,
thereby limiting the study temporally. A longer period of
sampling may have helped to delineate the duration of the
anticoagulated state induced by dalteparin.
In conclusion, the ACT and aPTT are sensitive to IV
dalteparin at clinically relevant doses. These data suggest
that the ACT may have the potential to be integrated into
an IV dalteparin monitoring strategy. The ability to monitor
dalteparin may facilitate the use of LMWH in PCI and in
other invasive procedures such as coronary artery bypass
surgery.
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